

Amendments to the Abstract

~~The invention relates to a~~ A GLP-1 derivative is provided including an amino acid sequence of GLP-1(7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)_n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is Arg, Arg-NH₂, Lys, Lys-NH₂ or Hse) added to the C-terminus of the peptide having a GLP-1 activity. These derivatives are ~~derivatives~~ highly absorbable via a mucous membrane. ~~In the invention, the~~ The GLP-1 derivative can be conferred with resistance to dipeptidyl peptidase IV by substituting amino acid 8 in its GLP-1 amino acid sequence with Ser, or with resistance to trypsin by substituting amino acids 26 and 34 with Gln and Asn, respectively.

~~_____ The absorption efficiency of absorption of the GLP-1 derivatives of the invention via~~
mucous membranes can be further improved by preparing a composition using a charge-regulated fat emulsion regulated to be negatively charged thereon.